DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
The partnership integrates Claritev’s innovative solutions with Lantern’s Specialty Care Platform to optimize healthcare costs for Lantern’s footprint. MCLEAN, Va.--(BUSINESS WIRE)-- Claritev ...
- Humacyte plans to advance CTEV into first-in-human study in CABG - DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results